Skip to main content
GCA temporal artery

Giant Cell Arteritis Novel Treatment Options

Giant cell arteritis is associated with significant treatment related morbidity due to the dependence on glucocorticoids as a treatment option. After sixty years of therapeutic stagnation, these are exciting times in the management of GCA. At this year's ACR Convergence meeting, encouraging data

Read Article
Cardiovascular Disease for TNFi vs JAKi: Dr Jon Giles discusses abstracts #0831and #0958 presented at the ACR21 annual meeting.https://t.co/O90HInaS7z https://t.co/MdHVyxfkaW
Dr. John Cush @RheumNow( View Tweet )
Nov 29, 2021
Autoinflammatory: PAH in AOSD, VEXAS, JAKi in Still's, Role of labs in infections vs. flares Drs.Cush, Yusof, Mehta, Petryna and Tate review autoinflammatory data presented at #ACR21. @Yuz6Yusof @bella_mehta @DrPetryna @uptoTate https://t.co/oeAprkSBWZ https://t.co/1g9yRRFJqf
Dr. John Cush @RheumNow( View Tweet )
Nov 24, 2021
Pipeline

Emerging Therapies in Spondyloarthritis: A Promising Pipeline

Nov 24, 2021

Growing awareness of spondyloarthropathies over the last two decades has led to a better understanding of the pathophysiology of spondyloarthritis, and subsequently increased interest in more distinct, disease state specific treatment options.

Read Article
jon.kay

Does Control of Inflammation Lower Cancer Risk?

Nov 23, 2021

Dr. Jonathan Kay's provocative video addresses whether the increased cancer risk associated with tofacitinib (Tofa) seen in the Pfizer Oral Surveillance (1133) study represents a real increased risk, an increased risk relative to a decreased risk with TNF inhibitors (TNFi) or an actual decreased

Read Article
ICYMI: JAKi Safety: Dr. Aurelie Najm ( @AurelieRheumo) interviews Dr. Choy about JAKi safety data, including abstracts #0958, #1940 and #1941 presented at the #ACR21 annual meeting.https://t.co/LOM8zz62Pm https://t.co/83HRCZdtfE
Dr. John Cush @RheumNow( View Tweet )
Nov 22, 2021
ICYMI: Perspectives on CV safety: JAK inhibitor (Tofacitinib) and TNF inhibitorshttps://t.co/g5FirIK9Af https://t.co/63s7IaKhl7
Dr. John Cush @RheumNow( View Tweet )
Nov 21, 2021
First JAKi Failure: What next? Dr. Aurelie Najm ( @AurelieRheumo) discusses abstract #1442 presented at the #ACR21 annual meeting.https://t.co/NCO8VeNsjb https://t.co/bSN34AFTtt
Dr. John Cush @RheumNow( View Tweet )
Nov 18, 2021
heart.jpg (keep)

Perspectives on CV safety: JAK inhibitor (Tofacitinib) and TNF inhibitors

Safety comparisons of JAKi (tofacitinib) vs. TNFi from Oral Surveillance showed that, in patients with active RA on MTX and aged >50 years with one or more CV risk factors, that there was numerically more MACE events, malignancies, and VTE especially in higher dose.

Read Article
RheumNow Podcast square

RheumNow Podcast - ACR 2021 Rehash (the good stuff..)

Nov 12, 2021

The ACR 2021 meeting has concluded. Dr. Jack Cush recounts a few more great abstracts from this past week’s virtual meeting.

Read Article
heel enthesitis spur calcaneal

Predicting RA, and Treatment of Subclinical Arthritis

Identifying patients that will develop RA in situations of seropositivity without overt clinical arthritis or identifying patients with undifferentiated oligo/polyarthritis that will develop RA remains a challenge in the field of rheumatology. 

Read Article
Upadacitinib PsA w/axial involvement - post-hoc analysis of SELECT-PsA 1 and S-PsA-2 Statistically greater response in axial dz compared to placebo in both dz dx'ed by investigator alone & on investigator + PRO-based criteriahttps://t.co/YPc5fx9wAR#ACR21 Abst1945 @RheumNow

Pedro Castillo @_Castillo_Pedro( View Tweet )

Nov 09, 2021
Put those two RF together (essentially nailing down RA pts at risk of cancer): age >65 or ever smoked, all tofa vs TNFi: HR 1.55 (1.05-2.30) age >65 or ever smoked, tofa 5 bid vs TNFi: HR 1.44 (0.93-2.24) neither RF, all tofa vs TNFi: HR 1.16 (0.53-2.55) #ACR21 @RheumNow https://t.co/Uvr4wBhFVF
Nov 09, 2021
#ACR21 Ab#1939: Tofa CV Outcome (STAR-RA) ▶️Pooled data does not show ⬆️ risk of CVD ▶️Trend in pts w prior CVD -HR 1.27 (0.95-1.7), cannot r/o CVD risk in pts w risk factors Less clear than oral surveillance data, but concerns in those w riskshttps://t.co/JOKNyYVZfX @Rheumnow https://t.co/GGYJfxcqhc
Nov 09, 2021
ORAL Surveillance malignancy risk @RADoctor . Numerically higher at both doses tofacitinib compared to TNFi . Abstr#1940 #ACR21 @RheumNow https://t.co/uc2k5EaiRq
Richard Conway @RichardPAConway( View Tweet )
Nov 09, 2021
STAR-RA, CV risk large insurance datax3 tofa vs TNFi all comers: HR 1.01 (0.83-1.23) one CV RF + any MTX: HR 1.24 (0.90-1.69) prev CVD: HR 1.27 (0.95-1.70) not sig but surely okay to say baseline CV risk + tofa makes me a little nervous? @SeoyoungCKim #ACR21 ABST1939 @RheumNow https://t.co/LmmL5zgv9u
Nov 09, 2021
ORAL Surveillance: MACE and malignancy are getting all the attention... but did you know that non-zoster infections are also more likely with tofacitinib vs TNFis? #ACR21 ABST1684 @RheumNow https://t.co/GiBkvPYs4j
Nov 09, 2021
Serious infections beyond herpes zoster in both doses of #tofacitinib v #TNFi in Oral Surveillance. Note this outcome was not powered to be stat sig. it is a comparison of SIE events #ACR21 abst#1684 @RheumNow https://t.co/uqME6ABXuC
Nov 09, 2021
Handy overview of Jak/STAT pathways in rheumatic diseases and available inhibitors (Dr. Joost Swart). Happening now in the Pediatrics Hub (New Therapies & Biologic Safety in Pediatric Rheumatology​). #ACR21 #pedsrheum https://t.co/i4bYr4GKOP
Katie Poholek @kpoho( View Tweet )
Nov 09, 2021
Deucravacitinib is a novel, oral, selective TYK2 inhibitor in PsA and selectively mediates specific inflammatory pathways (IL-23, IL-12, Type I IFN). Listen to my interview with Prof. Oliver Fitzgerald on this and his highlights https://t.co/3UJCwbHsLC @RheumNow #ACR21 Abst#490 https://t.co/OWZDHhcQ9q
Dr. Antoni Chan @synovialjoints( View Tweet )
Nov 09, 2021
Upadacitinib showed similar efficacy in AS pts compared to PsA pts with axial involvement ⭐️PsA pt w/ axial involvement and AS pts with differences in baseline characteristics #ACR21 @RheumNow Abs#1802https://t.co/QvyayelBYU https://t.co/50dNQm30vf
Robert B Chao, MD @doctorRBC( View Tweet )
Nov 09, 2021
Phase 2 Placebo/Deucravacitinib 6mg/12mg od study ACR20 at 16 weeks of 31.8%/52.9%/62.7% respectively. Efficacy observed across TNFi and body weight subgroups. Safety profile similar to Phase 3 trials in patients with psoriasis @RheumNow #ACR21 Abst#1820 https://t.co/bOfEZdqN5Z https://t.co/EjMwWISM80
Dr. Antoni Chan @synovialjoints( View Tweet )
Nov 09, 2021
PsA.Hands_.jpg

The Need for Comparative Treatment Trials in Psoriatic Arthritis

Psoriatic arthritis is currently experiencing a burgeoning selection of treatment options. While this is a very welcome development in a disease which has had less treatment options compared to RA, it leaves us with a difficult conundrum: which agent to choose for an individual patient.

Read Article
Will a FDA black box warning change your JAKi practice? In May 2019, the EMA put out a warning about VTE with tofacitinib. In this French cohort, did it change the kind of pts they initiated on JAKi? no, not it did not😊 A window into the US future? #ACR21 ABST1245 @RheumNow https://t.co/QI95E1gepg
Nov 09, 2021
Safety profile of #upadacitinib in #RA, #PsA, #AnkylosingSpondylitis 👉🏼AE rates similar across UPA, ADA & MTX in RA, and UPA & ADA in PsA 👉🏼No new safety risks with long-term use 👉🏼#Herpeszoster & incr CPK more common w/ UPA vs ADA/MTX Abs#1691 #ACR21 @RheumNow https://t.co/tKYi65kB5r
Mrinalini Dey @DrMiniDey( View Tweet )
Nov 09, 2021
×